ZENTALIS PHARMACEUTICALS stock was originally listed at a price of $23.20 in Apr 3, 2020. The stock has traded between $29.51 and $87.19 in the past 52 week period. Following the completion of the transaction, the chief operating officer now owns 110,000 shares in the company, valued at $3,307,700. Zentalis Pharmaceuticals Inc. (ZNTL) is priced at $24.75 after the most recent trading session. Zentalis Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Complete Zentalis Pharmaceuticals Inc. stock information by Barron's. View real-time ZNTL stock price and news, along with industry-best analysis. Fundamental data provided by AAII's Stock Investor Pro, Refinitiv and /I/B/E/S and are updated through the previous trading day. Get Zentalis Pharmaceuticals (ticker: ZNTL) real-time share value, investment, rating and financial market information from Capital. The stock opened Monday's trading at $33.00 after closing last trading day at $33.97. The stock's lowest day price was 46.96. What is ZNTL's Earnings Per Share (EPS) forecast for 2022-2024? The stock's last close p. 1 year ago - Benzinga Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock Report $29.03 (3.31%) Volume: 415.233k. In connection with the Corporate . Company's stock value dipped to $25.96 during the trading on the day. 28/06/2022 14:15:17 1-888-992-3836 Free . Zentalis Pharmaceuticals employs 177 staff and has a market cap (total outstanding shares value) of 0.00. Log In. It is calculated by multiplying the stock price by the number of shares outstanding. Zentalis Pharmaceuticals Llc employs 177 . Zentalis Pharmaceuticals Inc (ZNTL) stock is trading at $22.93 as of 1:51 PM on Friday, Jun 10, a decline of -$2.89, or -11.19% from the previous closing price of $25.82. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid . As a result of the Corporate Conversion, all holders of units of Zentalis Pharmaceuticals, LLC became holders of shares of common stock of Zentalis Pharmaceuticals, Inc. Seeking Alpha 37d Zentalis Pharmaceuticals appoints. Sell. Zentalis Pharmaceuticals shares last traded at $20.54, with a volume of 485 shares. 29.03 +0.93 (3.31%) At close: Jul 1, 2022 4:00 PM. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the closing of. View the latest Zentalis Pharmaceuticals Inc. (ZNTL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Zentalis Pharmaceuticals has raised a total of $517.1M in funding over 5 rounds. Over the next 52 weeks, Zentalis Pharmaceuticals has on average historically risen by 22.3% based on the past 1 years of stock performance. Zentalis Pharmaceuticals Inc (ZNTL) stock is trading at $26.52 as of 4:00 PM on Tuesday, May 17, an increase of $2.11, or 8.64% from the previous closing price of $24.41. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. . Their stock opened with $18.00 in its Apr 7, 2020 IPO. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock. Both the companies also plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic . NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small. Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday. Foghorn Therapeutics presently has a consensus price target of $24.00, suggesting a potential upside of 84.05%. Ticker: ZNTL. What analysts recommend for ZNTL stock, on a scale from 1 (buy) to 5 (sell). ZNTL is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. Stronger Stock . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers . 10835 Road to the Cure Suite 205 San Diego, CA 92121. Cancel. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved . is the total value of all of a company's outstanding shares. While the stock has lost 50% over the past four . Find real-time ZNTL - Zentalis Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. ZNTL: Get the latest Zentalis Pharmaceuticals Inc stock price and detailed information including ZNTL realtime prices, CAGR, performance, comparison with BTC and other assets This net worth approximation does not reflect any other assets that Dr. Bunker may own. Contact Email info@zentalis.com. Zentalis Pharmaceuticals has a consensus price target of $74.43, suggesting a . Find real-time ZNTL - Zentalis Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Real-time trade and investing ideas on Zentalis Pharmaceuticals Inc ZNTL from the largest community of traders and investors. Zentalis Pharmaceuticals Inc 30.66 1.63 (5.62%) Watch. Zentalis Pharmaceuticals Inc 30.66 1.63 (5.62%) Watch. On average, they predict Zentalis Pharmaceuticals' stock price to reach $74.43 in the next twelve months. Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells. For the readers interested in the stock health of Zentalis Pharmaceuticals Inc. (ZNTL). . Cancel. Get the latest Zentalis Pharmaceuticals Inc (ZNTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. exchange on which registered Common Stock, $0.001 par value ZNTL The Nasdaq Global Market per share Indicate by check mark whether the registrant is an emerging . Sign Up. Several equities research analysts have . That means that investors have to take special care when deciding whether or not to invest in pharmaceutical companies and the like. The stock has traded between $24.77 and $27.61 so far today. According to the issued ratings of 6 analysts in the last year, the consensus rating for Zentalis Pharmaceuticals stock is Buy based on the current 6 buy ratings for ZNTL. What analysts think ZNTL will be worth. Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. One such company that has been circulating in the news a lot lately is Zentalis Pharmaceuticals. About Zentalis Pharmaceuticals. Zentalis Pharmaceuticals, LLC (ZNTL) Stock Price, News & Info | The Motley Fool Zentalis Pharmaceuticals, LLC (ZNTL) Nasdaq Global Market ZNTL $23.94 $1.83 8.3% Price as of June 21, 2022, 4:00 p.m.. The company belongs in the Biotechnology industry, Healthcare sector and employs 110 people. About the Company USD. With ZENTALIS PHARMACEUTICALS stock trading at $21.38 per share, the total value of ZENTALIS PHARMACEUTICALS stock (market capitalization) is $996.95M. DOW 0.00%. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) COO Kevin D. Bunker sold 25,000 shares of the firm's stock in a transaction on Tuesday, July 5th.The stock was sold at an average price of $30.07, for a total value of $751,750.00. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Dr. Bunker owns 135,000 shares of Zentalis Pharmaceuticals stock worth more than $3,686,850 as of June 23rd. Zentalis Pharmaceuticals Inc. Stock Forecast NASDAQ:ZNTL BUY SELL. NASDAQ 0.00%. Zentalis Pharmaceuticals Inc is a biotechnology business based in the US. This suggests a possible upside of 142.8% from the stock's current price. The stock has traded between $22.64 and $26.38 so far today. (NASDAQ: ZNTL) Zentalis Pharmaceuticals's current Earnings Per Share (EPS) is -$3.87. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) COO Kevin D. Bunker sold 25,000 shares of the firm's stock in a transaction on Tuesday, July 5th.The stock was sold at an average price of $30.07, for a total value of $751,750.00. Buy. Zentalis Pharmaceuticals Inc.'s (NASDAQ: ZNTL) Stock Price Will Be Bearish Or Bullish In 2022 stocksregister 21 hrs ago Looking Closely at the Growth Curve for Zentalis Pharmaceuticals Inc. (ZNTL) The stock had previously closed at $21.38, but opened at $22.24. Full . Log In. April 27, 2022 - 7:00 am. Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) stock closed at 29.03 per share at the end of the most recent trading day (a 3.31 % change compared to the prior day closing price) with a volume of 432.71K shares and market capitalization of 1.65B.Is a component of indices and it is traded on NASDAQ exchange. 05 May. The Company's products include ZN-c5 and ZN-c3. 6 Wall Street research analysts have issued 1-year price targets for Zentalis Pharmaceuticals' stock. Trending now. News Zentalis Pharmaceuticals Inc. No significant news for ZNTL in the past two years. . Sign Up. DOW 0.00%. Rooms Shows Rankings Earnings Newsletters Shop. Zentalis Pharmaceuticals, Inc is primarely in the business of pharmaceutical preparations. $92.80. This net worth approximation does not reflect any other assets that Ms. Epperly may own. Best predictor for any stock is listed at the stock pages. In Thousands, USD TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019; EV: Zentalis Pharmaceuticals, Inc. (ZNTL) has been beaten down lately with too much selling pressure.
Off-campus Housing Coastal Carolina, Stores Like Love Bonito, Little Nightmares 2 Steamunlocked, 4th Standard Social Guide, Zentalis Medical Writer Salary, Kia Telluride Blowing Cold Air,